LIXTE BIOTECHNOLOGY HOLDINGS, INC. — fact timeline

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Secured Promissory Note with NOMAD Transportable Power Systems, Inc. valued at $6,500,000 (effective 2026-06-17).

“On June 17, 2026, in connection with the transactions contemplated by the Merger Agreement, the Company issued a Secured Promissory Note in the aggregate principal amount of $6,500,000 (the “ Note ”) to NOMAD. The proceeds of the Note will be used (i) to repay in full NOMAD’s outstanding obligations under that certain Loan and Security Agreement, dated as of February 12, 2024, between NOMAD and BPCP Investment Holdings, LP, as successor in interest to Bay Point Capital Partners II, LP, with such portion of the proceeds being disbursed by the Company directly to BPCP Investment Holdings, LP on behalf of NOMAD, and (ii) for working capital and general corporate purposes of NOMAD.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Purchase Agreement with certain accredited investors valued at approximately $16.6 million (effective 2026-06-02).

“On June 2, 2026, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), 2,366,503 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), and Pre-Funded Warrants (“Pre-Funded Warrants”) to purchase 258,859 shares of Common Stock, at an offering price of $6.31 per share (or $6.30 per Pre-Funded Warrant).”

Stuart D. Porter was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amended and Restated Share Exchange Agreement with Orbit Capital Inc. valued at Amends and restates the Share Exchange Agreement dated November 21, 2025 (effective 2025-11-21).

“On March 6, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Liora Technologies Europe Ltd, a subsidiary of the Company (“Liora”) and Orbit Capital Inc., (“Orbit”), entered into an Amended and Restated Share Exchange Agreement with an effective date of November 21, 2025 (the A&R Agreement).”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Collaborative Research Agreement with The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).

“On December 17, the Company entered into a Collaborative Research Agreement with the Anderson Cancer Center (the “Research Agreement”).”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amendment No.2 with GlaxoSmithKline LLC and The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).

“On December 17, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into Amendment No.2 (“Amendment No.2”) to the GSK & LIXTE Supported Collaborative Study (the “Collaborative Study”) by and between the Company, GlaxoSmithKline LLC (“GSK”) and the University of Texas M.D. Anderson Cancer Center”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Royalty Agreement with Orbit Capital Inc. (effective 2025-12-16).

“On December 16, 2025, the Company and Orbit Capital Inc., a Cayman Islands Corporation (the “Royalty Holder”) entered into a termination letter (“Termination Letter”), whereby the Company and the Royalty Holder terminated that certain Royalty Agreement dated November 24, 2025 (the “Royalty Agreement”).”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Placement Agent Agreement with Spartan Capital Securities, LLC valued at 6.0% of the aggregate gross proceeds raised in the Offering and agreed to reimburse the Placement Ag (effective 2025-12-18).

“Pursuant to a Placement Agent Agreement dated as of December 18, 2025 (the “Placement Agent Agreement”), the Company engaged Spartan Capital Securities, LLC (the “Placement Agent”) to act as the Company’s exclusive placement agent in connection with the Offering.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $4.3 million (effective 2025-12-18).

“On December 18, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”) 526,342 shares (the “Common Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”), Pre-Funded Warrants (“Pre-Funded Warrants”) to purchase 525,000 shares of Common Stock at an offering price of $4.09 per share (or $4.08999 per Pre-Funded Warrant) and Common Warrants (“Common Warrants”) to purchase 1,051,342 shares of Common Stock at an offering price of $3.96 per share.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Filed Certificate of Designations creating Series C Convertible Preferred Stock with 2,700 shares, $1,000 stated value, no dividends, limited voting rights, liquidation preference senior to junior securities, convertible into common stock subject to beneficial ownership limitations (effective 2025-11-24).

“On November 24, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (the “ Certificate of Designation ”) with the Secretary of State of the State of Delaware.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. completed an acquisition involving Orbit Capital Inc. for 2,700 shares of the Company's Series C Preferred Stock, $1,000 stated value per share; 10.56 Bitcoin and 300 Ethereum; $440,000 in cash; and a royalty agreement (closed 2025-11-24).

“pursuant to a lease agreement. At the closing, the Company agreed to pay the following consideration (the “ Consideration ”) in exchange for the Shares: (i) issue to Seller 2,700 shares of the Company’s Series C Preferred Stock, $1,000 stated value per share (the “ Series C Preferred Stock ”) having such rights and preferences as set forth in the”

Bastiaan van der Baan departed as President and Chief Scientific Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer”

Geordan Pursglove was appointed as Chief Executive Officer and Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“April 17, 2025, the Company received notice that the Nasdaq Hearings Panel (the “Panel”) had granted the Company an extension in which to regain compliance with all continued listing rules of the Nasdaq Capital Market. The Panel’s determination follows a hearing on April 3, 2025, at which the Panel considered the Company’s plan to regain compliance with the Equity Rule. As a result of the extension, the Panel granted the Company’s request for continued listing on the Nasdaq Capital Market, provided that the Company demonstrates compliance with the Equity Rule and all other continued listing re”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“om the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the “Stockholders’ Equity Requirement”). On October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders’ Equity Requirement, which outlined the Company’s proposed initiatives to regain compliance by raising equity capital through various registered”

Jan Schellens was appointed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.”

James Miser departed as Chief Medical Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“On May 24, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) provided notice to Dr. James Miser that it has elected not to renew the employment agreement between the Company and Dr. Miser pursuant to which Dr. Miser has served as the Company’s Chief Medical Officer.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into License Agreement with National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH) valued at $50,000 (effective 2024-02-23).

“On February 23, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Patent License Agreement (the “License Agreement”) with the National Institute of Neurological Disorders and Stroke (“NINDS”) and the National Cancer Institute (“NCI”), each an institute or center of the National Institute of Health (“NIH”).”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Approve amendment to the 2020 Stock Incentive Plan to increase common shares issuable by 336,667 shares to a total of 750,000 shares at the 2023-11-27 meeting.

“Proposal 3 (amendment of the Stock Plan): Votes For Votes Against Abstain Broker Non-Votes 854,971 60,023 420 559,164”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Ratify the appointment of Weinberg & Company, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-27 meeting.

“Proposal 2 (appointment of accounting firm): Votes For Votes Against Abstain Broker Non-Votes 1,433,849 40,266 463 0”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Election of five director nominees to serve for a one-year term expiring at the 2024 annual meeting at the 2023-11-27 meeting.

“The results of the voting were as follows: Proposal 1 (election of directors): Each of the director nominees to the Company’s Board of Directors was elected as follows: Nominee Votes For Votes Withheld Broker Non-Votes Dr. Stephen Forman 856,934 58,480 559,164 Dr. Yun Yen 904,748 10,666 559,164 Regina Brown 905,057 10,357 559,164 Dr. René Bernards 905,489 9,925 559,164 Bas van der Baan 865,224 50,190 559,164”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Development Collaboration Agreement Amendment 2 with Netherlands Cancer Institute (NKI) and Oncode Institute valued at Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years (effective 2023-10-13).

“On October 13, 2023, the parties signed an amendment (“Amendment 2”) to expand the collaboration to study drug synergies of the Company’s lead compound, LB-100, with immunotherapy in various cancers. Under Amendment 2, the parties will seek to find synthetic lethal combinations in additional cancer types. Amendment 2 also extends the Collaboration Agreement for an additional two years.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Exclusive License Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. valued at No termination fee payable; no further payments owed by Company. (effective 2023-09-30).

“On October 4, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) received a counter-signed termination letter dated September 29, 2023 (the “Termination Letter”) with respect to the Exclusive License Agreement dated August 20, 2018 (the “License Agreement”) between the Company and H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), effective September 30, 2023.”

John S. Kovach was appointed as Executive Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Effective September 26, 2023, the Company appointed John S. Kovach, M.D. as Executive Chairman. Dr. Kovach will no longer act as the Company’s President and Chief Executive Officer, but will continue as the Company’s Chief Scientific Officer.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Securities Purchase Agreement valued at approximately $3,500,000 (effective 2023-07-18).

“On July 18, 2023, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Offering”), 583,334 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof), and common warrants to purchase up to 583,334 shares of common stock in a concurrent private placement, at a purchase price of $6.00 per share.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Filed a Certificate of Amendment to the Certificate of Incorporation to effect a 1-for-10 reverse stock split of common stock, effective June 2, 2023 (effective 2023-06-02).

“On June 1, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of its outstanding shares of common stock. The Amendment was effective on June 2, 2023 (the “Effective Time”).”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. shareholders approved Approval of Granting the Board discretionary authority to effectuate the Reverse Stock Split at the 2023-05-26 meeting.

“On May 26, 2023, the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to combine the Company’s outstanding shares of common stock into a lesser number of outstanding shares (the “Reverse Stock Split”) at a specific ratio up to a maximum of 1-for-10 split, with the exact ratio to be determined by the Company’s Board of Directors (the “Board”), in its sole discretion. Set forth below are the final voting results for the Reverse Stock Split Proposal: Proposal 1 – Approval of Granting the Board discretionary authority to effectuate the Reverse Stock Split. Stockholders of the Company approved granting the Board authority to effectuate the Reverse Stock Split. The voting results were as follows, based on 16,659,093 shares of common stock outstanding and entitled to vote: Votes For Votes Against Abstentions Broker Non-Votes 11,122,681 577,844 2,841 275”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Sales Agreement with WestPark Capital, Inc. valued at up to $10,000,000 (effective 2023-05-09).

“Item 1.02 Termination of a Material Definitive Agreement. At-the-Market Sales Agreement Effective May 9, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) terminated the at-the-market sales agreement (the “Sales Agreement”), dated September 20, 2021, with WestPark Capital, Inc. (“WestPark Capital”) relating to the possible sale of up to $10,000,000 of shares of its common stock, from time to time, through WestPark Capital.”

LIXTE BIOTECHNOLOGY HOLDINGS, INC.: Reduced the quorum for stockholder meetings from a majority to 33-1/3% of voting power (effective 2022-11-06).

“On November 6, 2022, the Board of Directors of the Company approved Amended and Restated Bylaws. The amendment to the Bylaws was solely in respect to Section 2.8 to reduce the quorum for the transaction of business and all meetings of the stockholders from the holders of a majority to 33-1/3% of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.”

Eric Forman changed role as Vice President and Chief Operating Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Promoted Eric Forman, the Company’s Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year.”

Bastiaan van der Baan was appointed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Effective as of June 17, 2022, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc. (the “Company”) appointed Bastiaan van der Baan to the Board as an independent director.”

Dr. René Bernards was appointed as director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.”

Philip Palmedo departed as Director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

“On May 9, 2022, Philip Palmedo informed the Company that he did not intend to stand for reelection at the next Annual Meeting of Stockholders of the Company.”